Estey EH - Search Results

1

Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment.

Walter RB, Othus M, Borthakur G, Ravandi F, Cortes JE, Pierce SA, Appelbaum FR, Kantarjian HA, Estey EH. Walter RB, et al. Among authors: estey eh. J Clin Oncol. 2011 Nov 20;29(33):4417-23. doi: 10.1200/JCO.2011.35.7525. Epub 2011 Oct 3. J Clin Oncol. 2011. PMID: 21969499 Free PMC article.

2

Clinical significance of plasma endostatin in acute myeloid leukemia/myelodysplastic syndrome.

Lai R, Estey E, Shen Y, Despa S, Kantarjian H, Beran M, Maushouri T, Quackenbuch RC, Keating M, Albitar M. Lai R, et al. Cancer. 2002 Jan 1;94(1):14-7. doi: 10.1002/cncr.10200. Cancer. 2002. PMID: 11815955 Free article.

3

Prolonged infusion of gemcitabine: clinical and pharmacodynamic studies during a phase I trial in relapsed acute myelogenous leukemia.

Gandhi V, Plunkett W, Du M, Ayres M, Estey EH. Gandhi V, et al. Among authors: estey eh. J Clin Oncol. 2002 Feb 1;20(3):665-73. doi: 10.1200/JCO.2002.20.3.665. J Clin Oncol. 2002. PMID: 11821446 Clinical Trial.

4

Proliferation and apoptosis in acute and chronic leukemias and myelodysplastic syndrome.

Lin CW, Manshouri T, Jilani I, Neuberg D, Patel K, Kantarjian H, Andreeff M, Estrov Z, Beran M, Keating M, Estey E, Albitar M. Lin CW, et al. Leuk Res. 2002 Jun;26(6):551-9. doi: 10.1016/s0145-2126(01)00170-9. Leuk Res. 2002. PMID: 12007503

5

Experience with gemtuzumab ozogamycin ("mylotarg") and all-trans retinoic acid in untreated acute promyelocytic leukemia.

Estey EH, Giles FJ, Beran M, O'Brien S, Pierce SA, Faderl SH, Cortes JE, Kantarjian HM. Estey EH, et al. Blood. 2002 Jun 1;99(11):4222-4. doi: 10.1182/blood-2001-12-0174. Blood. 2002. PMID: 12010830 Free article. Clinical Trial.

6

Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside.

Estey EH, Thall PF, Giles FJ, Wang XM, Cortes JE, Beran M, Pierce SA, Thomas DA, Kantarjian HM. Estey EH, et al. Blood. 2002 Jun 15;99(12):4343-9. doi: 10.1182/blood.v99.12.4343. Blood. 2002. PMID: 12036860 Free article. Clinical Trial.

7

Clinical relevance of vascular endothelial growth factor receptors 1 and 2 in acute myeloid leukaemia and myelodysplastic syndrome.

Verstovsek S, Estey E, Manshouri T, Giles FJ, Cortes J, Beran M, Rogers A, Keating M, Kantarjian H, Albitar M. Verstovsek S, et al. Br J Haematol. 2002 Jul;118(1):151-6. doi: 10.1046/j.1365-2141.2002.03551.x. Br J Haematol. 2002. PMID: 12100142 Free article.

8

Myelodysplastic syndrome is not merely "preleukemia".

Albitar M, Manshouri T, Shen Y, Liu D, Beran M, Kantarjian HM, Rogers A, Jilani I, Lin CW, Pierce S, Freireich EJ, Estey EH. Albitar M, et al. Among authors: estey eh. Blood. 2002 Aug 1;100(3):791-8. doi: 10.1182/blood.v100.3.791. Blood. 2002. PMID: 12130488 Free article.

9

A phase I study of idarubicin dose escalation with amisfostine and high-dose cytarabine in patients with relapsed acute myelogenous leukemia and myelodysplastic syndromes.

Garcia-Manero G, Faderl S, Giles F, Thomas D, Cortes J, O'Brien S, Davis J, Kantarjian HM, Estey E. Garcia-Manero G, et al. Haematologica. 2002 Aug;87(8):804-7. Haematologica. 2002. PMID: 12161355 Clinical Trial.

10

Ursodiol does not prevent hepatic venoocclusive disease associated with Mylotarg therapy.

Giles F, Garcia-Manero G, Cortes J, Thomas D, Kantarjian H, Estey E. Giles F, et al. Haematologica. 2002 Oct;87(10):1114-6. Haematologica. 2002. PMID: 12368170 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

379 results

Search Page